Skip to main content
. 2022 Jun 23;13:898493. doi: 10.3389/fimmu.2022.898493

Figure 8.

Figure 8

Validation of IGFBP7-based immune risk model. (A) DCA curve for assessment of the clinical usefulness of the risk model. (B) Nomogram for predicting the probability of 1-, 3-, and 5-year survival probability for BLCA patients. (C–J) Differences in clinicopathological features between the high- and low-risk groups in the TCGA cohort. **p<0.01; ***p<0.001.